As the real cause of Dupuytren’s disease is unknown to this day, it is not surprising that there are many different and conflicting suggestions for various type of management. Because of the multitude of suggestions, some of which are not really important to physicians, we will restrict our presentation to the discussion of radiotherapy and pharmacological treatment (DAHLKE, 1992; DAHMEN et al., 1967; HERBST et al., 1985; REIFFERSCHEID, 1951; VOIGT et al., 1980; LAMB, 1981; LECLERCQ et al., 2000).
KeywordsConservative Therapy Flexion Contracture Motion Improvement Leukemia Risk Fascial Tissue
Unable to display preview. Download preview PDF.